R&D is often the most cost-intensive and risky step in a new drug's life cycle yet often dictates the speed and adaptability of the innovation ecosystem. The time and capital required for biotech to translate a new concept or target into a clinical asset is substantial, and in the age of platform companies, the potential targets are vast. How do you know what targets to prioritize? Partnerships between biotech and pharma in early-stage R&D have become more common and often crucial for advancing target discovery. This panel will spotlight successful R&D collaborations leveraging innovative bioplatforms that integrate cutting-edge technologies like genomics, proteomics, and AI-driven analytics to identify novel therapeutic targets more efficiently. Pharma leaders will share insights on what they are looking to get out of biotech partnerships and how to attract a partner for early R&D success.